A synthetic adjuvant to enhance and expand immune responses to influenza vaccines.
Safe, effective adjuvants that enhance vaccine potency, including induction of neutralizing Abs against a broad range of variant strains, is an important strategy for the development of seasonal influenza vaccines which can provide optimal protection, even during seasons when available vaccines are not well matched to circulating viruses. We investigated the safety and ability of Glucopyranosyl Lipid Adjuvant-Stable Emulsion (GLA-SE), a synthetic Toll-like receptor (TLR)4 agonist formulation, to adjuvant Fluzone® in mice and non-human primates. The GLA-SE adjuvanted Fluzone vaccine caused no adverse reactions, increased the induction of T helper type 1 (T(H)1)-biased cytokines such as IFNγ, TNF and IL-2, and broadened serological responses against drifted A/H1N1 and A/H3N2 influenza variants. These results suggest that synthetic TLR4 adjuvants can enhance the magnitude and quality of protective immunity induced by influenza vaccines.
Infectious Disease Research Institute, Seattle, Washington, United States of America.
Rhea N
RN
Coler
Susan L
SL
Baldwin
Narek
N
Shaverdian
Sylvie
S
Bertholet
Steven J
SJ
Reed
Vanitha S
VS
Raman
Xiuhua
X
Lu
Joshua
J
DeVos
Kathy
K
Hancock
Jacqueline M
JM
Katz
Thomas S
TS
Vedvick
Malcolm S
MS
Duthie
Christopher H
CH
Clegg
Neal
N
Van Hoeven
Steven G
SG
Reed
D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000818:Animals; D003429:Cross Reactions; D016207:Cytokines / Q000096:biosynthesis; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D007111:Immunity, Cellular; D007252:Influenza Vaccines / Q000276:immunology*; D051379:Mice; D008807:Mice, Inbred BALB C; D011323:Primates
D000276:Adjuvants, Immunologic; D016207:Cytokines; D007252:Influenza Vaccines